Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, Therapeutic insights into the treatment of Sickle cell disease and β-thalassemias: Argonaute-2 decreases sickling of erythrocytes via up regulation of fetal HbF, 25/September/2014, 08.23 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org
Significance: This study suggests that Argonaute-2, by regulating the expression of its target gene, it may increase the levels of HbF. Thus, pharmacological formulations encompassing “Argonaute-2 activator” may be used to treat: (1) Sickle cell disease ; (2) β-thalassemias; and (3) disease conditions that has lower levels of HbF.
* Research cooperation